Johnson & Johnson Restarts VARIPULSE Sales Amid PFA Market Reconfiguration

Johnson & Johnson Varipulse Review of Sales Suspension Incident

In the field of medical technology, every new technological breakthrough may bring new hope to patients. Pulsed Field Ablation (PFA) As a cutting-edge technology in the field of cardiac electrophysiology, it has received much attention in recent years. Johnson & Johnson's Varipulse The platform is an important participant in this field.

2024 Year 11 Month, Johnson & Johnson Varipulse Pulsed Electric Field Ablation System Successfully Obtained FDA Approved for the treatment of drug-refractory, symptomatic paroxysmal atrial fibrillation patients, officially entering the market. , becoming one with Medtronic and Boston Scientific Corporation in possessing PFA Technology Approved for Treatment AFib The three major companies have launched their competition in the electrophysiology market. Since their introduction,Varipulse Actively carried out applications globally.As of 2025Year 1 Month 3 Days of treatment have already been administered. 3000 Multiple cases have also been completed in the United States. 130 Multiple external evaluation cases.

However,2025 Year 1 In a month, a piece of news broke Varipulse The promotion rhythm. Johnson & Johnson announced that, since 1 Month 5 Date,“Temporarily Suspended” All use its Varipulse Pulse Field Ablation (PFA) system in the United States. This decision was based on an investigation into four neurovascular events, including stroke incidents, reported in external assessments in the U.S.FDA Manufacturer and User Facility Device Experience (MAUDE) A stroke report in the database shows that a patient Varipulse Strokes occurred after treatment, and in Europe, at least two patients experienced Varipulse Strokes also occurred after the surgery.

Johnson & Johnson stated in a press release that it has suspended external evaluations in the U.S. and all activities in the U.S. out of caution. Varipulse Cases, while conducting an in-depth investigation into the root causes. Notably, due to the unique platform configurations utilized in external U.S. assessments, this suspension will not impact commercial activities outside the U.S. Varipulse Case Impact . This event has triggered widespread market attention, with Johnson & Johnson Medical's stock price falling, while competitors Boston Scientific and Medtronic's stock prices have risen.

Investigation Results and Resumption of Sales Decision

Temporarily Suspended Varipulse Following the use of the system in U.S. cases, Johnson & Johnson quickly launched a comprehensive and in-depth investigation. This investigation did not merely focus on the device itself but covered multiple key dimensions, including potential device-related factors, surgical procedures, and patient-specific factors, among others.

The survey results show,Varipulse The equipment itself is operating well, with no device malfunctions or defects that could potentially lead to neurovascular events. Regarding the availability across China, Varipulse No significant differences were found during performance evaluation. . This conclusion provides important equipment-level evidence for the resumption of sales, indicating that the equipment meets safety and performance standards in its design and manufacture.

Further analysis revealed that,The occurrence of neurovascular events is closely related to surgical procedures and individual patient conditions.Specifically, extensive ablation, overlapping ablation, and ablation outside the pulmonary veins can significantly increase the probability of neurovascular events. For instance, when a doctor performs excessive ablation during surgery or conducts multiple overlapping ablations in the same area, it may adversely affect the surrounding neurovascular tissues. The physical condition and physiological characteristics of different patients also play an important role in surgical outcomes. Some patients may already have issues such as fragile blood vessels or abnormal blood viscosity, which can be exacerbated during the surgery, thereby increasing the risk of neurovascular events like stroke.

Based on these survey results, Johnson & Johnson believes that resuming operations can be considered after taking corresponding measures. Varipulse The sales are feasible. The company plans to update Varipulse Global Instructions for Catheter Use, Incorporating Enhanced Guidance to Help Physicians Better Understand and Avoid Operations That May Lead to Risks. The New Instructions Will Provide Detailed Explanations of the Best Ablation Strategies Under Different Conditions, Including the Number of Ablations, Energy Intensity, and Site Selection, etc., to Minimize Surgical Risks.

Varipulse Platform and Technical Features

Varipulse As an important innovative achievement of Johnson & Johnson in the field of cardiac electrophysiology, the platform’s design and technical principles demonstrate the cutting-edge level of modern medical technology.The platform is mainly composed of Varipulse Catheter,TruPulse Generator and Carto 3 3D Composition of Cardiac Mapping System ，Each part closely collaborates to provide an efficient and precise solution for atrial fibrillation treatment.

From a technical perspective,Varipulse The core of the platform lies in pulsed field ablation (PFA) Technology and Carto 3 Combined with the mapping system.PFA The technology blocks abnormal electrical signal conduction that causes arrhythmia by applying short-pulse electric fields to cardiac tissue, creating irreversible tiny pores in the cell membrane. This ablation method is tissue-selective, effectively ablating target myocardial tissue while minimizing damage to surrounding blood vessels, nerves, and other tissues, thereby reducing the risk of surgical complications. Compared with traditional radiofrequency ablation and cryoablation technologies,PFA Technology has improved the safety of surgeries and the patients' tolerance while enhancing the treatment effectiveness.

Carto 3 The mapping system is Varipulse Another major technical highlight of the platform. As the world's leading three-dimensional cardiac mapping system,Carto 3 Capable of real-time, precise rendering of the heart's 3D electrophysiological map, providing an intuitive display of the heart’s electrical activity. During the surgical procedure, the physician can utilize Carto 3 The system clearly visualizes the electrical signal conduction pathways and abnormal areas inside the heart, allowing for more accurate localization of the ablation targets, thereby achieving precise treatment of atrial fibrillation lesions. This real-time visualization and feedback mechanism not only improves the success rate of the surgery but also significantly reduces the operation time. X Fluoroscopy time is reduced, decreasing the radiation dose received by both patients and doctors.

Varipulse The catheter, as a key component of the platform, is also uniquely designed. This catheter features a variable circuit and multi-electrode design, crafted from laser-cut nitinol tubing, offering excellent flexibility and shape memory characteristics. The size of the catheter's circular tip can be adjusted within a certain range. 25 Millimeters to 35 Flexible adjustment within millimeters, capable of adapting to the cardiac anatomical structures of different patients, ensuring good contact between the electrode and cardiac tissue. Meanwhile, the catheter is equipped with 10 An electrode, these electrodes can be bidirectionally steered, with one side steered. 180°, Bend adjustment on the other side 90°, allowing the catheter to easily access all four pulmonary veins, including the anatomically complex right inferior pulmonary vein, achieving comprehensive isolation and ablation of the pulmonary veins.

In terms of energy application,PFA In the skipped electrode (i.e., electrode 1 To the electrode 3) and each adjacent electrode between them (i.e., electrode 1 - 2 And 2 - 3) applied between with bipolar configuration, energy at 1800V. Each PFA Applications include all 3 A microsecond-long biphasic pulse sequence between two bipolar configurations, with a total application duration of approximately 250 Milliseconds. This precise energy control and pulse sequence design can ensure the effectiveness and safety of ablation, achieving effective ablation of the target tissue while avoiding unnecessary damage to cardiac tissue caused by excessive ablation.

Market Competition Landscape and Impact

In pulsed electric field ablation (PFA) market, the competitive landscape has been constantly evolving. Currently, Medtronic, Boston Scientific, and Johnson & Johnson are the main players in the market, with each of the three companies making progress in technology development, product approvals, and market promotion.

Medtronic, as a pioneer in the industry, in PFA Significant achievements have been made in the field. PulseSelect System at 2023 Pioneering Acquisition in the Year FDA Approved for the treatment of paroxysmal and persistent atrial fibrillation , becoming the first to be launched in the U.S. market PFA This landmark event gave Medtronic a competitive edge in the market.2024Year 10 Month, Medtronic's Sphere-9 And its matching use Affera The mapping and ablation system has also been obtained FDA Approval, making it the first in the industry to provide patients with two PFA Clinical Technology Pathway Companies. Medtronic, with its deep technical expertise in the electrophysiology field and extensive market channels, has achieved relatively widespread application of its products globally. It holds a significant position in terms of market share and brand influence.

Boston Scientific is also in PFA The market has performed exceptionally well. FARAPULSE System at 2021 Year 1 Month Obtained EU CE Certification, becoming the world's first commercialized PFA Product.2024 In the year, the system subsequently received approval in the United States. FDA, China NMPA And Japan PDMA Marketing Authorization , achieving a comprehensive layout in the global core market. With the help of FARAPULSE Following the successful launch of the system, Boston Scientific's electrophysiology business revenue achieved rapid growth.2024 Electrophysiology business sales in the fourth quarter of the year were 6.49 billion dollars, with total annual sales of 19 billion dollars, increasing by nearly 171% And 138% , demonstrating its strong market competitiveness. The company continuously iterates its products, with a new generation of catheters featuring 3D mapping capabilities. FARAWAVE NAV As of 2024 Year 10 Month Obtained in the United States FDA Registration certification further consolidates its position in the market.

Johnson & Johnson Varipulse System Obtained in Japan PDMA, EU CE And the United States FDA After approval, it was originally expected to PFA Capture a share of the market. However, the suspension of sales due to the stroke incident has significantly impacted its market promotion and competitive landscape. During the sales suspension period, Johnson & Johnson's market share was directly affected, with its potential market share possibly being seized by competitors. Medtronic and Boston Scientific may seize this opportunity to intensify their market promotion efforts, expand their customer base, and further solidify their market positions.

From the market response, analysts generally believe that if Boston Scientific and Medtronic's systems do not have similar issues, they will benefit from this incident. For instance, some analysts have stated. “This news makes us [Boston Scientific] More optimistic, because our recent downgrade mainly focused on [Medtronic] And [Johnson & Johnson] PFA Competition Risks Brought by Product Launch” , which indicates that the market is optimistic about the potential advantages of competitors in this incident. Even if Varipulse Resume sales, its brand image may also be damaged, and doctors may be more cautious in choosing to use it. In Johnson & Johnson's Admire In key studies,277 Out of patients, there are 3 People experience cerebrovascular events, a risk that has been magnified in this sales suspension incident, potentially making doctors Varipulse The safety concerns lead to a preference for products from other competitors.

In the future,PFA The market competition will remain fierce. With the continuous development of technology and the gradual maturation of the market, companies need to constantly optimize product performance and improve safety and effectiveness to meet the needs of doctors and patients. Strengthening market promotion and brand building, as well as enhancing product awareness and reputation, are also key for companies to gain a competitive edge. For Johnson & Johnson, recovery Varipulse Sales are just the first step; regaining the trust of doctors and patients and enhancing the market competitiveness of the product will be important challenges it faces.

Clinical Applications and Patient Safety Considerations

In clinical applications,Varipulse The emergence of the system has brought new options for atrial fibrillation treatment, but this stroke incident has also raised many considerations among doctors and patients regarding its safety.

From the doctor's perspective, they usually maintain a cautious and rational attitude when facing new technologies.Varipulse Although the system's pulsed electric field ablation technology has unique advantages, the occurrence of stroke events has made doctors more cautious when using the device. They will more strictly evaluate the patient's condition and physical status to determine whether it is suitable for use. Varipulse Proceed with treatment. For patients with high-risk factors for stroke, such as underlying vascular diseases or hypercoagulable states, doctors may weigh the pros and cons more carefully, or even opt for other more established treatment options.

Doctors will also reflect on and improve the surgical procedures. They will pay more attention to the choice of ablation strategies, strictly control the number of ablations, energy intensity, and location, and avoid high-risk operations such as excessive ablation, overlapping ablation, or ablation outside the pulmonary veins. Doctors will also strengthen communication with patients, fully inform them of the risks of the surgery and possible complications, allowing patients to make treatment decisions based on a comprehensive understanding of the situation.

For patients, safety is always their primary concern. Upon learning that Varipulse After the system experiences a stroke event, the patient's trust in the technology may be affected to a certain extent. When choosing a treatment plan, they will be more cautious and gain a deeper understanding of the safety and effectiveness of various treatment methods. Some patients may be hesitant due to concerns about risks. Varipulse The system hesitated and turned to seek other more traditional but relatively safer treatment methods.

This does not mean that patients will completely give up their expectations for new technologies. If Johnson & Johnson can effectively reduce surgical risks and improve through improved measures,Varipulse If the system is safe, patients may still consider choosing this technology for treatment. Patients also hope that doctors can provide more professional and comprehensive advice to help them make the most suitable treatment choice.

In order to ensure patient safety, Johnson & Johnson has implemented a series of improvement measures. Update Varipulse Global Instructions for Catheter Use Are Key Initiatives. The new instructions provide detailed descriptions of procedural standards and precautions, offering clearer guidance to physicians. It emphasizes the need to reasonably select ablation energy and duration based on the patient's specific condition during ablation procedures to avoid excessive ablation. Additional requirements for preoperative patient evaluation and postoperative monitoring have been included to ensure timely identification and management of potential risks.

Strengthening communication and training with healthcare professionals is also an important aspect. Johnson & Johnson organizes academic seminars, online training courses, and other methods to convey the latest research findings and safety operation guidelines to doctors. These training activities not only help doctors better master... Varipulse The use of the system can also enhance their awareness and response capabilities regarding surgical risks. The company has also established a dedicated feedback mechanism to encourage doctors to share problems and experiences encountered in clinical applications, so as to promptly improve and optimize the product.

In terms of patient information sharing, Johnson & Johnson educates patients about atrial fibrillation treatment through various channels, including Varipulse The systematic treatment principles, advantages, and potential risks. The company has released detailed product information and safety tips on its official website and has also created easy-to-understand promotional materials to help patients better understand the treatment process and precautions. Through these measures, patients can gain a more comprehensive understanding of their condition and treatment options, enabling them to participate more rationally in treatment decision-making.

Future Outlook and Industry Trends

With Varipulse Resume sales, its future development is full of opportunities as well as challenges. On the positive side,Varipulse With unique technical advantages, it and Carto 3The integration of mapping systems provides a precise and efficient solution for atrial fibrillation treatment, offering a certain level of competitiveness in the market. If Johnson & Johnson can effectively address the negative impact caused by stroke incidents—through measures such as strengthening product quality control, optimizing surgical operation guidelines, and enhancing physician training to regain the trust of doctors and patients—then Varipulse Expected to gain a foothold in the market.

From the market trend, pulsed electric field ablation (PFA) technology is gradually becoming the mainstream development direction in the field of cardiac electrophysiology. According to research by Citibank,PFA With its efficient, safe, and precise features, the technology is expected to 2025 Surpassed radiofrequency ablation in years, becoming the primary method for treating atrial fibrillation. According to Frost & Sullivan data, China PFA Market Size 2025 will reach by the year 13 billion yuan, and maintain rapid growth, expected by 2032 Reached in 163 100 million yuan, with a compound annual growth rate of 43.73% . This indicates PFA The technology has broad market prospects worldwide.Varipulse As PFA One of the important products of the technology will also benefit from this market trend.

In terms of technological upgrades, the future PFA Technology is expected to achieve breakthroughs in multiple dimensions. The precision of equipment will be further improved, and by combining 3D imaging with real-time cardiac activity monitoring technology, doctors will be able to more accurately locate ablation targets, increasing the success rate and safety of surgeries. Operational procedures will also continue to be simplified, with the development of automated and intelligent equipment making surgeries more efficient and reducing the impact of human factors on surgical outcomes. Some companies are exploring PFA Combined with other forms of energy (such as radiofrequency, cryotherapy, etc.), a multi-functional ablation catheter has been developed to meet the treatment needs of different patients.

In terms of market penetration, with FDA Yes PFA Rapid approval of equipment,PFA Technology is accelerating into the global market. Doctors PFA The acceptance is also increasing, and many clinical practices have proven its safety and effectiveness. In the future, with the deepening of market education and the accumulation of doctors' operational experience,PFA The market penetration of the technology is expected to increase further.

In terms of indication expansion, currently PFA Mainly used for the treatment of atrial fibrillation, but in the future, its application areas may further expand to the treatment of other arrhythmias. Some studies have shown,PFA The technology also has potential applications in the treatment of ventricular tachycardia, atrial tachycardia, and other arrhythmias.PFA Technology may also show certain application potential in other medical fields (such as tumor ablation).

Despite PFA The technology has broad prospects, but Varipulse Also faces fierce market competition. Medtronic and Boston Scientific in PFA The market has gained a certain first-mover advantage, with its products occupying an important position in terms of market share and brand influence. Chinese manufacturers such as Jinjiang Electronics and Huitai Medical are also actively making plans. PFA Field, continuously launching competitive products. Johnson & Johnson needs to continuously optimize.Varipulse Performance and safety, strengthen market promotion and brand building to meet the challenges from competitors.

For patients, regardless of how technology evolves, the safety and efficacy of treatment remain their primary concerns. In the future, with PFAWith the continuous improvement of technology and the accumulation of clinical experience, it is believed that safer and more effective treatment options can be provided to patients, improving their quality of life and reducing the health threats posed by arrhythmia diseases such as atrial fibrillation.